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Abstract
Background: Protein kinase C (PKC) isoforms are potential targets for breast cancer therapy. This study was
designed to evaluate which PKC isoforms might be optimal targets for different breast cancer subtypes.
Results: In two cohorts of primary breast cancers, PKCa levels correlated to estrogen and progesterone receptor
negativity, tumor grade, and proliferative activity, whereas PKCδ and PKCε did not correlate to clinicopathological
parameters. Patients with PKCa-positive tumors showed poorer survival than patients with PKCa-negative tumors
independently of other factors. Cell line studies demonstrated that PKCa levels are high in MDA-MB-231 and
absent in T47D cells which proliferated slower than other cell lines. Furthermore, PKCa silencing reduced
proliferation of MDA-MB-231 cells. PKCa inhibition or downregulation also reduced cell migration in vitro.
Conclusions: PKCa is a marker for poor prognosis of breast cancer and correlates to and is important for cell
functions associated with breast cancer progression.
Background
Breast cancer is a heterogeneous disease which encom-
passes several subgroups with different morphology,
genetic changes, and response to therapies [1,2]. It is
therefore important to gain more insight into relevant
therapeutic targets for each subgroup to optimize tai-
lored treatment protocols for individual patients.
Numerous intracellular signaling proteins have been
suggested to be promising targets for blocking the
malignancy of breast cancer cells. The protein kinase
C (PKC) isoforms are examples of such potential thera-
peutic targets.
PKC is a family of serine/threonine kinases involved in
several processes including proliferation, differentiation,
apoptosis, and migration. The PKC isoforms are divided
into three subgroups depending on the structure of the
regulatory domain: classical (PKCa, bI, bII, and g), novel
(PKCδ, ε,a n dθ), and atypical (PKCζ and ι/l)i s o f o r m s .
Classical and novel PKCs contain a diacylglycerol
(DAG)-binding C1 domain and are therefore regulated
by activation of pathways that lead to DAG generation.
Atypical PKCs are DAG-insensitive and regulated in a
different manner [3].
Several studies have implicated the DAG-sensitive
classical and novel PKC isoforms in promoting malig-
nant features of breast cancer cells. PKCa has been
coupled to estrogen receptor (ER) negativity [4] and
estrogen-independent growth of cultured cells [5,6] and
patients with PKCa-negative tumors had better response
to endocrine treatment compared to patients with
PKCa-positive tumors [7,8]. Moreover, increased PKCa
expression leads to a more aggressive phenotype [4] and
is associated with resistance to cytostatic drugs in
MCF-7 cells [9,10]. PKCa is also evaluated as a thera-
peutic target for breast cancer [11]. However, PKCa
levels are reduced in breast cancer compared to normal
breast tissue [12,13]. Thus, there is evidence for both a
promoting and a suppressing role for PKCa in breast
cancer.
T h er o l eo fP K C δ in breast cancer is ambiguous.
Patients with PKCδ-positive tumors show better endo-
crine response compared to patients with PKCδ-negative
tumors [8] and PKCδ has been shown to be crucial for
UV light-induced apoptosis of cultured breast cancer
cells [14]. However, several studies point to a pro-
tumorigenic role of PKCδ in breast cancer. PKCδ can
induce resistance to tamoxifen and irradiation in cul-
tured breast cancer cells [15,16] and has been shown to
promote both metastasis [17-19] and proliferation [20]
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have recently shown that depletion of PKCδ is sufficient
to drive breast cancer cells into apoptosis [21].
PKCε has frequently been assigned oncogenic effects
in breast cancer. Expression levels of PKCε have been
shown to correlate with tumor grade, HER2 expression,
ER negativity, and poor survival in breast cancer
patients. Moreover, in MDA-MB-231 breast cancer cells,
downregulation of PKCε reduced the tumor growth and
metastatic capacity in mice [22]. There is also evidence
that PKCε protects cells against apoptotic insults
[23-25].
Taken together, the available in vitro and in vivo data
highlight PKCa,P K C δ,a n dP K C ε as future candidates
for targets in breast cancer therapy and as markers for
disease prognosis. However, so far there is limited
knowledge on the potential of the different isoforms as
diagnostic and prognostic markers in breast cancer. This
study sheds light on this issue by analyzing the expres-
sion levels of these PKC isoforms in primary breast can-
cer tissue and our results indicate that PKCa is a
potential marker of breast cancer aggressiveness.
Methods
Cell culture
All cell lines were obtained from ATCC. MCF-7, MDA-
MB-231, and MDA-MB-468 breast cancer cells were
maintained in RPMI 1640 medium (Sigma) supplemen-
ted with 10% fetal bovine serum (FBS; Invitrogen),
1 mM sodium pyruvate (PAA laboratories Gmbh),
100 IU/ml penicillin, and 100 μg/ml streptomycin (both
Gibco). T47D cells were grown in DMEM supplemented
with 10% FBS, 10 mM HEPES (PAA laboratories
Gmbh), 100 IU/ml penicillin, and 100 μg/ml streptomy-
cin. The media for MCF-7 and T47D cells were addi-
tionally supplemented 0.01 mg/ml insulin (Novo
Nordisk A/S).
Transfections
For siRNA transfections, cells were seeded at 35-50%
confluency and grown in complete medium without
antibiotics for 24 hours. Cells were transfected for 48
hours using 4 μl/ml Lipofectamine 2000 (Invitrogen)
and 40 nM siRNA (Invitrogen, table 1) in Optimem
(Gibco) according to supplier’s protocol.
Plasmid transfections were carried out for five hours
replacing normal medium with Optimem containing
2 μl/mL Lipofectamine 2000 and 2 μg/mL DNA accord-
ing to supplier’s protocol. Plasmids encoding PKC con-
structs fused to enhanced green fluorescent protein
(EGFP) have been described previously [26].
Tumor material
Cohort I originally consisted of tumors from 114 patients
diagnosed with breast cancer at Umeå University Hospital
and treated according to regional guidelines. The cohort is
described in table 2. Due to lack of tumor material in the
tissue microarray, 42-60 tumors could be analyzed,
depending on the parameter investigated. Ki-67 had been
classified in two groups <20% and >20% positive cells.
Cohort II included 512 consecutive breast cancer cases
diagnosed at the department of Pathology, Malmö Uni-
versity Hospital, between 1988 and 1992. The cohort is
d e s c r i b e di nt a b l e2 .D u et ol a c ko ft u m o rm a t e r i a li n
the tissue microarray, 223-263 tumors could be ana-
lyzed, depending on the parameter investigated. Ki-67
had been classified in three groups, 0-10%, 11-25% and
26-100% positive cells.
The cohorts represented a mix of all histological sub-
types in proportions corresponding to the common inci-
dence. The construction of tissue microarrays and
clinicopathological properti e so ft h ec o h o r t sh a v eb e e n
described in detail elsewhere [27-32]. Ethical permissions
were obtained from the Lund and Umeå Ethical Boards.
The number of tumors that could not be evaluated for
PKC expression due to lack of material is indicated as
not evaluated in the tables.
Cell pellet arrays
Cells were washed in phosphate-buffered saline (PBS)
and fixed for 25 minutes in 4% paraformaldehyde in
PBS with Mayer’s hematoxylin (5 μl/ml) present during
the last 5 minutes. The cells were pelleted, paraformal-
dehyde was removed and they were thereafter incubated







Table 2 Characteristics of the cohorts investigated
Cohort I II
Number of patients 114 512
Age at diagnosis, median (range) 60 (30-80) 65 (27-96)
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Page 2 of 14over night in 70% ethanol followed by dehydration using
increasing concentrations of ethanol and finally xylen.
After dehydration, cell pellets were embedded in paraffin
and arranged in a cell line array.
Immunohistochemistry
Sections (4 μm) of the paraffin blocks were dried, depar-
affinized, rehydrated and microwave-treated in 1× target
retrieval solution with high pH (DAKO). All sections
were stained in a DAKO Techmate™ machine and visua-
lized using DAB. The antibodies used were PKCa
(1:2000), PKCδ (1:1000), PKCε (1:400; all Santa Cruz
Biotechnology, product numbers sc-208, sc-937 and
sc-214), and Ki-67 (1:200; DAKO). All tissue microarray
slides of a cohort were stained simultaneously with the
same staining solutions ensuring identical conditions for
each tumor. PKC stainings were scored according to
cytoplasmic staining intensity were 0 representing lack
of staining, 1 low staining, 2 moderate staining, and
3 strong staining. All cohorts were examined indepen-
dently by two investigators and disconcordant results
were re-evaluated. For Ki-67 analyses of breast cancer
cell lines, Ki-67 staining intensity was scored as nega-
tive-low or moderate-strong staining.
Sample preparation and Western blot
Cells were washed twice in ice-cold PBS and lyzed with
RIPA buffer (10 mM Tris-HCl pH 7.2, 160 mM NaCl,
1% Triton-X 100, 1% sodium deoxycholate, 0.1% sodium
dodecyl sulfate, 1 mM EDTA, 1 mM EGTA) supple-
mented with 40 μl/ml complete protease inhibitor
(Roche Applied Science) for 30 minutes on ice. Lysates
were cleared by centrifugation at 14,000 × g for 10 min-
utes at 4°C.
Proteins were separated with SDS-PAGE and trans-
ferred to polyvinylidene difluoride membranes (Milli-
pore). Membranes were blocked with PBS containing
0.05% tween and 5% non-fat milk, and probed with anti-
bodies towards PKCδ (1:500), PKCε (1:500), PKCa
(1:3000), and actin (1:2000; MP Biomedicals, clone C4).
Proteins were visualized with horseradish peroxidase-
labeled secondary antibody (Amersham Biosciences)
using the SuperSignal system (Pierce Chemical) as sub-
strate. The chemiluminescence was detected with a
CCD camera (Fuji Film).
Analysis of cell growth (WST-1 assay)
Cell were seeded at a density of 2000 cells per well in
96-well culture plates, and incubated for 24 hours. For cell
line comparison, viable cell number was measured 24 and
48 hours after seeding. For experiments with inhibition or
activation of PKC, 2 μM Gö6976 (Calbiochem) or equal
volume DMSO, or 16 nM 12-O-tetradecanoylphorbol-13-
acetate (TPA; Sigma) was added in complete medium
(CM) or serum-free medium (SFM) 24 hours after seed-
ing, and cells were incubated for 72 hours prior to estima-
tion of viable cell number. The amount of viable cells was
assessed by a WST-1 cell viability assay (Roche Applied
Science). Absorbance was measured in an ELISA plate
reader Antos 2020 (Antos Labtech Instruments).
Immunofluorescence and confocal microscopy
Immunofluorescence of PKCa w a sd o n ea sd e s c r i b e d
[33] using Alexa Fluor 488-conjugated secondary anti-
bodies. Cells were examined with a Zeiss LSM 710 confo-
cal system using standard settings for Alexa Fluor 488.
Cell cycle analysis
MDA-MB-231 cells were seeded at a density of 100,000
cells per 35 mm cell culture dish and transfected with
siRNA. After transfection, cells were incubated in SFM
or CM for 24 hours. Cells were trypsinized and fixed in
70% ethanol for 20 minutes at -20°C, washed in PBS,
and incubated with a solution containing 3.5 μMT r i s -
HCl pH 7.6, 10 mM NaCl, 50 μg/ml propidium iodide
(PI), 20 μg/ml RNase, and 0.1% igepal CA-630 for
20 minutes on ice in order to label DNA. 10,000 events
were acquired on the FL-2 channel for the PI signal.
Sample acquisition and analyses were performed with
CellQuest software (Becton Dickinson).
Wound healing assay
MDA-MB-231 or MCF-7 cells were seeded at a density
of 150,000 cells per 35 mm cell culture dish and trans-
fected with siRNA. After transfection, a scratch was
made with a 200 μl pipette tip in a confluent area of the
cell culture dish. Photographs of a selected area of each
scratch were taken at indicated time points. For experi-
ments with PKC inhibitors, MDA-MB-231 cells were
seeded at a density of 350,000 cells per 35 mm cell cul-
ture dish and incubated for 24 hours before a scratch
was made and PKC inhibitors were added. Photographs
of a selected area of each scratch were taken 0 and 16
hours after scratching. The remaining wound area was
measured using ImageJ software.
Statistics
For TMA analysis, correlations between variables were
calculated using Pearson’s two-tailed significance test.
Differences in distribution of various clinicopathological
parameters in regard to PKC expression were also calcu-
lated using the c
2-test. The Kaplan-Meier analysis and
the log rank test were used to illustrate differences
between recurrence-free survival (RFS) and breast can-
cer-specific survival (BCSS) according to PKC expres-
sion. Cox regression proportional hazards models were
used to estimate the impact of PKCa expression on
breast cancer-specific survival in both univariate and
Lønne et al. Molecular Cancer 2010, 9:76
http://www.molecular-cancer.com/content/9/1/76
Page 3 of 14multivariate analysis, adjusted for Nottingham histologi-
cal grade (NHG), age, lymph node status, and tumor
size of cohort II. For in vitro experiments, the signifi-
cance of difference was assessed by analysis of variance
(ANOVA) followed by Duncan’s multiple range test.
The difference was considered significant if the p-value
was < 0.05. All statistical calculations were performed
using SPSS V.11.0.
Results
PKC expression in breast cancer tumors
Two cohorts of primary breast cancers (see experimen-
tal procedures for details) were analyzed for expression
of PKC isoforms. Several batches of antibodies were
tested to identify antibodies that did not cross-react
with other isoforms. Cross reaction is a notorious pro-
blem for analyses of PKC isoforms. For PKCa,P K C δ,
and PKCε we had access to antibodies that did not
cross-react with other isoforms (Figure 1A and 1B). As
can be seen in Figure 1A there is only strong immuno-
reactivity in some of the cells where the cognate isoform
has been overexpressed. In Figure 1B it can be seen that
downregulation with siRNA abolishes or markedly
diminishes the staining with the antibody towards the
cognate isoform.
When present in a tumor, all of the PKC isoforms inves-
tigated were generally cytoplasmic and expressed in all of
the tumor cells. Therefore, only the cytoplasmic staining
intensity was accounted for in the analyses. Figure 1C-J
show examples of tumors with different staining intensities
of PKCa, from negative to strong staining.
Initially a TMA of a smaller cohort (cohort I) was
evaluated (Table 3 and 4). There was a significant corre-
lation between PKCa staining intensity and lack of ER
(p < 0.001) and progesterone receptor (PR; p = 0.002) as
well as with tumor grade (p = 0.001) and proliferation
rate (Ki-67; p < 0.001). PKCa levels did not correlate
significantly with other clinicopathological parameters
such as local or distal metastases (Table 3). For PKCδ
and PKCε there were no significant correlations with
any of the clinicopathological parameters analyzed
(Table 3).
A larger cohort (cohort II; Table 3 and 4) was then
analyzed for expression levels of PKCa, since this iso-
form correlated to several clinicopatohological para-
meters in the first cohort, and PKCε, since our data
somewhat contradict a published study [22]. The results
from cohort II corroborated the findings in cohort I,
where tumors with high PKCa levels had a higher pro-
liferation rate (p < 0.001), were ER (p < 0.001) and PR-
negative (p < 0.001), and of a higher histological grade
(p < 0.001). Furthermore, a c
2 analysis demonstrated
that there is not an equal distribution of tumors with
high and low PKCa-levels in the different histological
subgroups in cohort II (Table 4). The skewed distribu-
tion is related to the tumors of medullary subtype.
A tumor was defined as medullary if it fulfilled the fol-
lowing criteria: 1) lymphocytoplasmic reaction, 2) micro-
scopic circumscription, 3) a syncytial growth pattern,
and 4) poorly differentiated nuclear grade and high
mitotic rate. For this group two out of twelve investi-
g a t e dt u m o r s( 1 7 % )h a dh i g hP K C a expression levels
whereas the corresponding number for all evaluated
breast cancers was five of 250 (2%). Only 8% of the
medullary tumors were PKCa-negative, compared to
72% for all tumors. Thus, there is an overrepresentation
of medullary carcinomas among tumors with high
PKCa levels. For PKCε, the findings were similar to
cohort I, with no correlation to any relevant clinico-
pathological parameters.
PKCa expression is associated with poor prognosis
We next analyzed the relationship between the expres-
sion of PKCa and PKCε and 10-year survival of the
patients (Figure 2). As illustrated in figure 2A, lower
PKCa levels were associated with a significantly pro-
longed 10-year RFS (p = 0.050). A similar trend was
also seen for 10-year BCSS, but this did not reach statis-
tical significance (Figure 2C; p = 0.116). Since the
majority of the tumors are negative for PKCa and the
other groups (staining intensity 1-3) are small, a dichot-
omized variable defined as absent staining versus any
staining was used for the same analyses of recurrence-
free and breast cancer-specific survival. When dichoto-
mized, PKCa positivity was associated with a non-signif-
icant trend towards a poorer 10-year RFS, figure 2B;
p = 0.074). However, patients with PKCa-negative
tumors had a significantly improved 10-year BCSS
compared to patients with PKCa-positive tumors
(Figure 2D; p = 0.016). We also performed a Cox regres-
sion proportional hazards analysis, demonstrating esti-
mates of relative risks (RR) according to PKCa
expression in univariate and multivariate analyses,
adjusted for age at diagnosis, tumor size, NHG, node
status and ER expression (Table 5). This revealed that
the association between PKCa positivity and a poor
10-year BCSS was independent of established prognostic
parameters (multivariate RR = 2.123, 95% CI 1.092 to
4.126, p = 0.026).
Since a majority of the medullary carcinomas analyzed
were PKCa-positive and patients with these tumors gen-
erally have good prognosis [34] we also examined
10-year BCSS after excluding patients with medullary
carcinomas and found that PKCa remained an indepen-
dent prognostic factor (Table 5).
Recurrence-free or breast cancer-specific 10-year sur-
vival was not significantly influenced by PKCε expres-
sion, neither for all groups (staining intensity 0-3) nor
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(Figure 2E-H). A higher cutoff was chosen for dichoto-
mization of PKCε due to a smaller proportion of nega-
tive tumors.
PKC expression in breast cancer cell lines
To evaluate whether different breast cancer cell lines
may represent the PKC isoform expression pattern in
tumors, we measured PKC levels in four breast cancer
cell lines (Figure 3A). High PKCa levels were seen
in MDA-MB-231 cells compared to MCF-7 and
MDA-MB-468 cells. PKCa was undetectable in T47D
cells. PKCδ levels were higher in MCF-7 cells, whereas
for PKCε no major differences in expression levels could
be noted.
To investigate whether the relationship between PKCa
and a high proliferation rate observed in the tumors can
be seen in cell lines as well, we examined the prolifera-
tion rate of the cell lines (Figure 3B and 3C). T47D,
which had no detectable PKCa, was the least prolifera-
tive cell line, supporting the tumor data. On the other
hand, for MDA-MB-231 which clearly had the highest
Figure 1 Immunohistochemical stainings of primary breast cancer and validation of antibody specificity. MCF-7 cells were transfected
with vectors encoding PKCa (a), PKCδ (δ), or PKCε (ε) (A) and MDA-MB-231 cells were mock-treated or transfected with siRNA targeting PKCa
(a), PKCδ (δ), or PKCε (ε) (B). Pellets of transfected cells were arranged in a cell line array and immunohistochemistry was performed with
antibodies towards indicated PKC isoforms. (C-J) Examples of immunohistochemical staining of PKCa in breast cancer specimens from cohort II
showing negative (C and G), low (D and H), moderate (E and I), and intense (F and J) staining with 20× magnification (C-F) and with 40×
magnification (G-J).
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Ki-67 staining intensity (Figure 3B). For the cell lines
with lower but detectable PKCa levels, MCF-7 and
MDA-MB-468, the corresponding numbers were 88%
and 91%, respectively. This did not differ significantly
from MDA-MB-231 cells which would not be expected
considering that the fraction of positive cells was close
to 100% in these cell lines. The Ki-67 data were sup-
ported by the growth rate of the cell lines as estimated
by a ratio of viable cell number after 48 h in culture
with the number obtained after 24 h (Figure 3C).
PKCa is crucial for breast cancer cell proliferation under
serum-free conditions
To further examine whether PKCa is important for pro-
liferation of breast cancer cells, the effects of a PKC
activator and an inhibitor were studied (Figure 4A-C).
Under serum-free conditions, activation of PKC by TPA
was not sufficient to increase cell growth, as indicated
by the amount of viable cells which represents the sum-
mative effect of proliferation and cell death. TPA did
influence PKCa as seen by a relocation of PKCa to the
plasma membrane and enrichment in the nucleus of
both MCF-7 and MDA-MB-231 cells (Figure 4D). This
indicates that PKCa is activated but the total levels of
PKCa were also reduced following TPA treatment (Fig-
ure 4E) which complicates the estimation of the net
effect of TPA on PKCa in the cells.
Gö6976, an inhibitor of classical PKCs, did not signifi-
cantly reduce the number of cells indicating that PKCa
activity is not critical for the growth of breast cancer
cells under normal conditions.
PKCa has been shown to promote proliferation inde-
pendently of its catalytic activity [35]. This fact together
with the fact that both TPA and Gö6976 can have unspe-
cific effects beside modulation of PKCa activity led us to
m o r es p e c i f i c a l l ya n a l y z et h er o l eo fP K C a by using
siRNA oligonucleotides followed by analysis of cell cycle
distribution. PKCa levels were downregulated in MDA-
MB-231 cells with both siRNAs targeting PKCa and this
did not influence the expression levels of the other PKC
isoforms investigated (Figure 5A). Only one of the PKCa
oligonucleotides (a #1) significantly influenced the cell
cycle distribution when cells were grown in serum-con-
taining complete medium (CM; Figure 5B). The oligonu-
cleotide slightly decreased the amount of cells in S-phase
compare to control. However, under serum-free medium
(SFM) downregulation of PKCa with either siRNA led to
significantly decreased amount of cells in S-phase com-
pared to control cells (Figure 5C). The result indicates
that PKCa plays an important role for proliferation of
cells particularly under sub-optimal conditions. Under
optimal growth conditions PKCa may be redundant for
proliferation.
PKCa activity is necessary for migration of breast cancer
cells
In breast cancer, PKCa has been associated with an
increased ability of cells to migrate, since overexpression
of PKCa has been shown to promote migration and
metastasis of breast cancer cells [4,36,37]. Based on this
we aimed at examining the importance of endogenous
PKCa for breast cancer cell motility. Wound healing
assays were performed with MDA-MB-231 cells in the
absence or presence of PKC inhibitors (Figure 6A). Inhi-
bition of classical PKCs (Gö6976) or classical and novel
PKCs (GF109203X) suppressed the wound closure to
34% and 56%, respectively, of the DMSO treated cells,
indicating that PKC activity is important for the ability
of MDA-MB-231 cells to migrate. Since PKC inhibitors
are isoform-unspecific, we downregulated PKCa with
siRNA in MDA-MB-231 cells prior to a wound-healing
assay, to more specifically study the role of PKCa in
migration. However, downregulation of PKCa did not
affect the migration of MDA-MB-231 cells (Figure 6B).
Table 3 Associations between PKCa, PKCδ, and PKCε
intensity and clinicopathological variables in cohort I and
II.
Cohort I II
Variable PKCa PKCδ PKCε PKCa PKCε
NHG
r 0.401 -0.049 -0.029 0.247 -0.011
p 0.001 0.719 0.833 <0.001 0.863
n 60 57 55 249 263
Estrogen receptor
r -0.482 0.210 -0.016 -0.334 0.068
p <0.001 0.120 0.907 <0.001 0.273
n 59 56 54 244 261
Progesterone receptor
r -0.402 -0.081 -0.216 -0.280 0.062
p 0.002 0.554 0.120 <0.001 0.342
n 58 55 53 223 240
Ki-67 positivity
r 0.535 0.229 0.280 0.295 -0.056
p <0.001 0.144 0.069 <0.001 0.363
n 46 42 43 244 261
Nodal status
r -0.027 0.095 -0.002 0.029 0.028
p 0.842 0.495 0.987 0.666 0.667
n 56 54 52 224 233
Distant metastasis
r 0.159 0.162 -0.064 0.090 0.037
p 0.226 0.227 0.642 0.159 0.556
n 60 57 55 247 261
r: Pearson’s correlation coefficient. p < 0.05 in bold. n: number of tumor
samples.
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compared to the other cell lines investigated in this
study (Figure 3A). Transfection of these cells with
siRNA targeting PKCa might not sufficiently reduce the
PKCa levels. A comparison with MCF-7 cells (Figure
6C) actually demonstrates that following siRNA treat-
ment of MDA-MB-231 cells the PKCa levels in these
cells are roughly the same as in MCF-7 cells. Therefore,
to obtain a more substantial PKCa depletion we down-
regulated PKCa in MCF-7 cells and thereafter per-
formed a wound healing assay (Figure 6E). PKCa
silencing in MCF-7 cells did not influence the other
PKC isoforms investigated (Figure 6D). In these cells
downregulation of PKCa significantly reduced migration
into the wound to 55% of the control cells (Figure 6E).
The results suggest that PKCa activity is crucial for
migration of breast cancer cells in vitro.
Discussion
Several studies have suggested that DAG-sensitive PKC
isoforms contribute to the progression of breast cancer
and the malignant characteristics of breast cancer cells.
In particular the PKCa,P K C δ, and PKCε isoforms have
been highlighted as potential targets for therapy of
breast cancer or of specific subsets of the disease. This
led us to design this study in which the expression of
these PKC isoforms in primary breast cancer tumors has
been examined to assess their utility as markers of
tumor aggressiveness.
To substantiate the analysis, two different cohorts of
primary breast cancer tumors were used, and the results
from the cohorts were similar. We found significant cor-
relations between PKCa levels and several markers of
tumor aggressiveness including ER negativity. A correla-
tion between PKCa levels and ER negativity has also
been observed in a recent study [8] using 70 tumors
from patients that had received systemic endocrine ther-
apy. They also showed that high PKCa levels predicted
a worse outcome in response to endocrine therapy,
which is also supported in an earlier study with a smal-
ler number of patients [7]. Our data, as demonstrated in
two separate cohorts, firmly establish the relationship
between PKCa and ER negativity. In addition, we iden-
tify a clear correlation between PKCa and PR negativity,
and a positive correlation with tumor grade and high
proliferation rate, further supporting the notion that
Table 4 Associations between PKCa, PKCδ, and PKCε intensity and histological type in cohort I and II.
Cohort I Ductal Lobular Medullary Mucinous
PKCa intensity 02 5 3 0 2
p* = 0.295 1 20 0 1 0
24 0 0 0
34 0 1 0
n.e. 42 3 0 2
PKCδ intensity 01 2 0 0 1
p* = 0.850 1 33 1 2 1
27 0 0 0
30 0 0 0
n.e. 43 5 0 2
PKCε intensity 00 0 0 0
p* = 0.800 1 12 0 1 0
22 9 1 1 2
39 0 0 0
n.e. 45 5 0 2
Cohort II Ductal Lobular Medullary Mucinous Tubular Mixed
PKCa intensity 0 124 17 1 10 14 13
p*<0.001 13 4 4 5 2 3 3
21 0 0 4 0 0 1
33 0 2 0 0 0
n.e. 168 52 3 5 17 17
PKCε intensity 02 1 0 0 0 0
p* = 0.328 1 38 9 7 4 5 5
29 0 1 9 4 7 9 7
34 1 5 1 1 1 7
n.e. 168 39 3 5 19 15
*c
2-test, p < 0.05 in bold, n.e. = not evaluated
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Page 7 of 14Figure 2 Recurrence-free survival and breast cancer-specific survival according to PKCa and PKCε expression. Kaplan-Meier estimates of
10 year recurrence-free survival (A-B and E-F) and breast cancer-specific survival (C-D and G-H) according to PKCa (A-D) and PKCε (E-H)
expression.
Lønne et al. Molecular Cancer 2010, 9:76
http://www.molecular-cancer.com/content/9/1/76
Page 8 of 14PKCa expression is associated with parameters related
to tumor aggressiveness. Finally, PKCa expression pre-
dicts a worse disease outcome with a significantly
poorer 10-year breast cancer-specific survival for
patients with primary tumors that were PKCa-positive.
The results from the multivariate analysis further indi-
cate that PKCa is an independent prognostic factor in
breast cancer.
However, other studies have indicated that PKCa
levels actually are decreased in breast cancer compared
to normal breast tissue [12,13]. This may not necessarily
contradict our findings since a vast majority of the can-
cer samples in our material were essentially PKCa-nega-
tive, which is in line with the notion that PKCa
downregulation is a common event during breast cancer
progression. Therefore, the published data, together
with our results, suggest that most breast cancers are
PKCa-negative, but that there are smaller subgroups
with higher PKCa levels, displaying more aggressive
clinicopathological features. If PKCa is to be used as a
target for breast cancer therapy these data highlight the
need to evaluate PKCa levels prior to such intervention.
In the largest cohort (II) there was also a significant
association of PKCa levels with histological subtypes.
Cancers with medullary histology were over-represented
in the group with high PKCa levels. In addition, the
only medullary cancer in cohort I was PKCa-positive.
In line with the tumor data demonstrating that PKCa
levels correlate with features of aggressiveness, an associa-
tion of PKCa with malignant features has also been seen
in breast cancer cell lines. Increased levels of PKCa corre-
late to and can induce tamoxifen [38,39] and multidrug
[9,10] resistance of ER-positive cell lines. In addition,
Table 5 Cox univariate and multivariate analysis of
breast cancer-specific survival in cohort II according to
PKCa expression in all patients and when patients with
medullary cancer are excluded.

























0.026 1.978 (0.984 to
3.975)
0.055
Multivariate analysis adjusted for Nottingham histological grade (I-II/III), age
(continuous), nodal status (0/1), tumor size (continuous), and ER (< or > 10%).
Figure 3 PKC expression and proliferation of breast cancer cell
lines. Western blots show expression levels of PKCa, PKCδ, and
PKCε in T47D, MCF-7, MDA-MB-231, and MDA-MB-468 breast cancer
cells (A). Cell pellets of proliferating cells were
immunohistochemically stained with anti-Ki-67. At least 200 cells per
cell line were scored for negative-weak or strong staining intensity
(B). The viable cell number was measured by WST-1 assay after 24
and 48 hours in culture. Ratio 48 h:24 h was used as an indicator of
cell proliferation (C). For all experiments, cells were grown in
complete medium. Western blots are representative of three
independent experiments. Data in B and C are mean ± SEM, n = 3.
Asterisks indicate statistically significant differences (* p < 0.05 and
** p < 0.01) compared to other cell lines (B and C).
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Page 9 of 14Figure 4 Cell growth analysis after activation or inhibition of PKC. T47D (A), MCF-7 (B), and MDA-MB-231 (C) breast cancer cells were
incubated in the absence or presence of 16 nM TPA in serum free medium (SFM) or 2 μM Gö6976, GF109203X, or equal volume of DMSO in
complete growth medium (CM) for 72 hours prior to WST-1 assay. Data (mean ± SEM, n = 3) represent the amount of viable cells expressed as
percent of viable cells obtained under control conditions. The localization of PKCa in control or TPA-treated MCF-7 and MDA-MB-231 cells was
examined with immunofluorescence followed by confocal microscopy (D). The levels of PKCa following treatment with TPA or Gö6976 were
analyzed by Western blot (E).
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proliferation which is in line with our tumor data [4], but
also make them more susceptible to apoptotic insults
[40,41]. We found that the cell line with no detectable
PKCa expression, T47D, had a lower percentage of Ki-67-
positive cells and slower growth rate than the other cell
lines, similar to the tumor data. However, the cell line
with the highest PKCa expression, MDA-MB-231, only
had marginally higher Ki-67 positivity compared with cell
lines with detectable but much lower expression. This may
be related to the fact that the fraction of Ki-67-positive
cells was high (97%) and could not be further elevated.
Neither inhibition of PKCa in the presence of serum
nor PKC activation under serum-starvation influenced
the growth of the cell lines in a manner that would sup-
port an essential role for PKCa for breast cancer cell
growth. A recent paper has shown that the PKCa pro-
tein, but not activity, is essential for glioma cell prolif-
eration [35]. We found that downregulation of PKCa
with siRNA caused a modest effect on cell cycle distri-
bution of MDA-MB-231 cells g r o w ni nc o m p l e t em e d -
ium. However, under serum-free conditions, PKCa
silencing clearly reduced the amount of proliferating
cells suggesting that, as in glioma cells, the PKCa pro-
tein, but maybe not its catalytic activity, supports prolif-
eration under sub-optimal conditions.
Studies in vitro have demonstrated that increasing the
PKCa expression in MCF-7 cells makes them more
migratory in response to PKC activation [42]. Our
experiments with cell lines indicate that PKC activity
supports migration of MDA-MB-231 cells. However,
downregulation of PKCa with siRNA in this cell line
did not affect cell migration. MDA-MB-231 cells have
high basal expression levels of PKCa and incomplete
downregulation of PKCa may explain the lack of effect
on cell migration. This assumption is supported by the
more efficiently suppressed wound healing upon down-
regulation of PKCa in MCF-7 cells. Our data therefore
indicate that PKCa activity is important for migration of
breast cancer cells, in line with previous findings using
PKCa overexpression. A migratory propensity might
facilitate the metastasation of a tumor. However, our
tumor data did not support a role for PKCa in dissemi-
nation. There was no correlation between PKCa expres-
sion and nodal or distant metastases. Thus, the effects
of PKCa on migration may primarily be of importance
in vitro.
For PKCδ t h e r ei sl e s si n f o r m a t i o nr e g a r d i n ge x p r e s -
sion levels in primary tumors. One study has shown
that low levels of PKCδ, particularly in combination
with high PKCa, predict resistance to endocrine therapy
[8]. In this study, we could not observe any significant
associations between PKCδ expression and relevant clin-
icopathological parameters. Thus, altered PKCδ
Figure 5 Cell cycle distribution of MDA-MB-231 cells with
downregulated PKCa. MDA-MB-231 cells were transfected with
two different siRNAs targeting PKCa (a #1 and a #2) or a control
oligonucleotide. After transfection, cells were incubated with
complete medium (CM) or serum-free medium (SFM) for 24 hours.
Adherent cells were thereafter subjected to Western blot (A) or
propidium iodide staining and flow cytometry (B and C). Western
blots are representative of three independent experiments. Data in
B and C (mean ± SEM, n = 3) show the percentage of cells in s-
phase.
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Page 11 of 14expression does not seem to be a prerequisite for breast
cancer progression.
PKCε has been proposed to be a marker of aggressive
breast cancer since its expression was reported to be
elevated in hormone receptor-negative breast cancers
with high tumor grade and HER2 amplification [22].
However, a relationship between PKCε expression and
tumor grade could not be confirmed in this study, sug-
g e s t i n gt h a ti tm i g h tn o tb ea p p a r e n ti nc o h o r t sr e p r e -
senting all histological subtypes of breast cancer. It is
possible that the level of PKCε is a marker of aggressive-
ness in more defined subgroups of breast cancer.
Conclusions
In conclusion, our findings demonstrate that expression
of PKCa correlates to both ER and PR negativity as well
as high histological grade and proliferation rate in breast
cancer. An important role for PKCa in breast cancer
cell proliferation was also observed in vitro.P K C a
expression is not associated with metastasis in breast
cancer samples, but PKCa activity supports migration of
breast cancer cells in vitro. Importantly, PKCa expres-
sion predicts for a poorer 10-year breast cancer-specific
survival, independently of established prognostic para-
meters. Thus, we propose that PKCa m i g h tb eau s e f u l
marker for prognostication and treatment stratification
in breast cancer.
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